139 related articles for article (PubMed ID: 26672633)
1. Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours.
Crona J; Norlén O; Antonodimitrakis P; Welin S; Stålberg P; Eriksson B
J Clin Endocrinol Metab; 2016 Feb; 101(2):445-52. PubMed ID: 26672633
[TBL] [Abstract][Full Text] [Related]
2. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.
de Mestier L; Hentic O; Cros J; Walter T; Roquin G; Brixi H; Lombard-Bohas C; Hammel P; Diebold MD; Couvelard A; Ruszniewski P; Cadiot G
Ann Intern Med; 2015 May; 162(10):682-9. PubMed ID: 25984844
[TBL] [Abstract][Full Text] [Related]
3. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
Wang SE; Su CH; Kuo YJ; Shyr YM; Li AF; Chen TH; Wu CW; Lee CH
Pancreas; 2011 Mar; 40(2):253-9. PubMed ID: 20966805
[TBL] [Abstract][Full Text] [Related]
4. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.
Kimura H; Ohtsuka T; Fujimoto T; Date K; Matsunaga T; Cases AI; Abe A; Mizuuchi Y; Miyasaka Y; Ito T; Oda Y; Nakamura M; Tanaka M
Pancreas; 2016 Aug; 45(7):947-52. PubMed ID: 26684862
[TBL] [Abstract][Full Text] [Related]
5. Pancreastatin predicts survival in neuroendocrine tumors.
Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
[TBL] [Abstract][Full Text] [Related]
6. Surgical Management of Pancreatic Neuroendocrine Tumors.
Clancy TE
Hematol Oncol Clin North Am; 2016 Feb; 30(1):103-18. PubMed ID: 26614371
[TBL] [Abstract][Full Text] [Related]
7. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
8. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Endocr Relat Cancer; 2017 Jul; 24(7):R261-R274. PubMed ID: 28483790
[TBL] [Abstract][Full Text] [Related]
9. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits.
Tanno L; Mayo D; Mills S; Takhar A; Cave J; Nolan L; Stedman B; Sundram FX; Abu Hilal M; Connor H; Pearce N; Armstrong T
Pancreatology; 2018 Apr; 18(3):304-312. PubMed ID: 29433805
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
[TBL] [Abstract][Full Text] [Related]
13. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
[TBL] [Abstract][Full Text] [Related]
14. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.
Singh S; Hallet J; Rowsell C; Law CH
Eur J Surg Oncol; 2014 Nov; 40(11):1517-22. PubMed ID: 25088936
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
[TBL] [Abstract][Full Text] [Related]
16. A unique case of a nonfunctional metastatic pancreatic neuroendocrine tumor transforming into an insulin-secreting tumor with an unusual clinical course.
Vashi PG; Gupta D; Dahlk S
Pancreas; 2011 Jul; 40(5):781-4. PubMed ID: 21673539
[No Abstract] [Full Text] [Related]
17. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
18. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
[TBL] [Abstract][Full Text] [Related]
19. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
20. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?
Qiu W; Christakis I; Stewart AA; Vodopivec DM; Silva-Figueroa A; Chen H; Woodard TL; Halperin DM; Lee JE; Yao JC; Perrier ND
Clin Endocrinol (Oxf); 2017 Jun; 86(6):791-797. PubMed ID: 28273369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
